Kristy M. Ainslie

Kristy M. Ainslie, PhD, is a Professor in the Department of Pharmacoengineering and Molecular Pharmaceutics at the University of North Carolina at Chapel Hill's Eshelman School of Pharmacy and a member of the UNC Lineberger Comprehensive Cancer Center. Her research develops immune-modulatory therapies using biomaterials to treat infectious and autoimmune diseases as well as cancer, with explicit focus on scalable production for resource-limited settings globally.

Dr. Ainslie's work integrates biomaterials science and immunology to engineer practical drug delivery systems, particularly using acetalated dextran (Ac-DEX) platforms. Her lab specializes in creating microparticles and nanofibers for antigen/vaccine delivery, cancer immunotherapy, and autoimmune disease treatment, prioritizing formulations adaptable to developing nations. Recent advancements include electrospray techniques for non-denaturing protein encapsulation and machine learning models for predicting drug release kinetics.

Her publication trajectory reveals consistent innovation in nanomedicine, with increasing emphasis on translational applications. Key trends include acid-responsive polymer systems for controlled therapeutic release, scalable manufacturing methods for global vaccine access, and immune-modulation strategies targeting T-regulatory cells for autoimmune conditions like multiple sclerosis.

Dr. Ainslie's accolades include:

• Sato Memorial International Award (2023)
• Controlled Release Society Fellow (2022)
• American Institute for Medical and Biological Engineering Fellow (2021)
• OSU Council of Graduate Students Distinguished Faculty Advising Award (2012)

She actively mentors PhD and Master's students, with recent advisees including Nicole Rose Lukesh, Sophie Mendell, and Ryan Woodring. Her lab comprises postdoctoral researchers like Pamela Tiet and Monica Johnson, supported by collaborative projects with institutions including Ohio State University. While specific grants aren't detailed, her high-impact publications and lab operations indicate substantial external funding.

The Ainslie Lab, headquartered at 4012 Marsico Hall, drives translational nanomedicine through interdisciplinary teams. It maintains active outreach initiatives like school science demonstrations and hosts international collaborators, reflecting its commitment to education and global health impact.